Diagnosis and Management of Genetic Lipodystrophy Syndromes and its Implications for Atherosclerosis.

PURPOSE OF REVIEW: This paper explores the diagnostic and management challenges associated with genetic lipodystrophy syndromes (LDs) and their implications for atherosclerosis and cardiovascular health.

RECENT FINDINGS: Genetic LDs, such as familial partial lipodystrophy (FPLD) and congenital generalized lipodystrophy (CGL), are characterized by abnormal fat distribution and significant metabolic complications. FPLD patients are often misdiagnosed as having type 2 diabetes; CGL patients may die early from noncardiovascular causes, giving the impression that cardiovascular disease is not frequent. Actually, these syndromes are associated with increased cardiovascular risks and early-onset atherosclerosis. Cardiovascular disease is common in LD patients; a high level of suspicion is essential for early diagnosis and effective management of genetic LDs to mitigate associated cardiovascular risks. Continued research into innovative therapies and a better understanding of the underlying mechanisms are crucial for improving patient outcomes and alleviating the healthcare burden of these syndromes.